Seborrhoeic dermatitis: antifungals and short steroid courses are what the trials back

Seborrhoeic dermatitis is the flaky, red, sometimes greasy-looking rash that settles on the scalp, eyebrows, the creases beside the nose, the ears and the mid-chest. On the scalp its mild form is dandruff. It is a chronic inflammatory skin condition, distributed worldwide, that commonly affects the scalp, face and body folds [s1]. The first thing to unlearn is that it is a hygiene problem: washing harder does not fix it, and over-washing can make it worse. What it needs is treatment aimed at the two things actually driving it — inflammation and skin yeast.

What causes it

Seborrhoeic dermatitis has a genuinely multifactorial cause. A 2026 systematic review of its molecular mechanisms describes a disorder involving immune dysregulation, oxidative stress, neuroendocrine signalling and disruption of the epidermal barrier–lipid axis [s3]. In the skin, that shows up as a Th1- and Th17-skewed immune response with cytokine and stress-signal upregulation, alongside impaired barrier function and altered lipid metabolism [s3]. Sitting on top of that biology is a yeast, Malassezia, which lives normally in oily skin; the fact that antifungal creams reliably improve the rash is the practical evidence that the yeast helps drive it [s1]. Put simply, the condition is an inflammatory over-reaction in oil-rich skin, partly provoked by a normal skin resident — which is why it flares and settles rather than going away for good, and why it is more common and more stubborn in some neurological conditions and in people with weakened immunity.

What actually helps — antifungals first

The best evidence for topical antifungals comes from a Cochrane review of 51 studies with 9052 participants [s1]. Ketoconazole was the most studied. Ketoconazole 2% showed a 31% lower risk of failed clearance of the rash compared with placebo, a risk ratio of 0.69 (95% confidence interval 0.59 to 0.81) at four weeks, though the evidence was rated low quality and varied a lot between trials [s1]. To put that in context, the median proportion of people not cleared in the placebo groups was 69% [s1]. Ciclopirox 1% performed similarly, with a lower failed-clearance rate than placebo, risk ratio 0.79 (0.67 to 0.94) [s1]. The two agents were comparable to each other, and no single antifungal clearly beat the others [s1].

Antifungals also compared well with steroids on the trade-off that matters for long-term use. Ketoconazole produced a remission rate similar to topical steroids, risk ratio 1.17 (0.95 to 1.44), but with 44% fewer side effects, risk ratio 0.56 (0.32 to 0.96) [s1]. That is the case for using an antifungal as the mainstay: comparable control, gentler on the skin over time.

Where steroids fit — and their limits

Topical anti-inflammatories have their own Cochrane review, covering 36 randomised trials with 2706 participants [s2]. Topical steroids produced total clearance far more often than placebo in short courses of four weeks or less, with a relative risk of 3.76 (1.22 to 11.56), and also reduced redness, scaling and itch [s2]. That makes a short steroid course a legitimate way to break a bad flare quickly.

The catch is what steroids are not good for: continuous long-term use on the face, where thinning skin and other local effects become a concern. Reassuringly, the review found calcineurin inhibitors (such as tacrolimus and pimecrolimus) roughly as effective as steroids for short-term clearance, risk ratio 1.08 (0.88 to 1.32), giving a steroid-sparing option for facial skin that needs ongoing control [s2]. Both reviews are candid that trials were mostly short — few looked beyond four weeks — and that effects on individual symptoms and on quality of life are poorly measured [s1][s2].

A realistic routine

The evidence-backed plan is straightforward. For the scalp, an antifungal shampoo — ketoconazole or ciclopirox — used regularly and left on for a few minutes is the base [s1]. For the face and folds, an antifungal cream is the mainstay, with a short course of a mild topical steroid, or a calcineurin inhibitor, to settle a flare [s1][s2]. Because the condition is chronic and relapsing, the aim is intermittent maintenance rather than a one-off cure; stopping treatment usually lets it return.

See a doctor if the rash is widespread, weeping or crusted, if it is not responding to over-the-counter antifungals, if it appears suddenly and severely in adulthood, or if it comes with other symptoms — severe or abruptly worsening seborrhoeic dermatitis can occasionally be a marker of an underlying condition and is worth a professional look rather than another bottle of shampoo.

This article is informational and is not medical advice.

Sources

• [s1] Topical antifungals for seborrhoeic dermatitis — Cochrane Database of Systematic Reviews, 2 May 2015. https://doi.org/10.1002/14651858.CD008138.pub3
• [s2] Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp — Cochrane Database of Systematic Reviews, 19 May 2014. https://doi.org/10.1002/14651858.CD009446.pub2
• [s3] Molecular Mechanisms in Seborrheic Dermatitis — Systematic Review — International Journal of Molecular Sciences, 19 March 2026. https://doi.org/10.3390/ijms27062799